Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT02924701
Active, not recruiting Observational

sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis

NCT02924701 · tracked via the Priya Life Science Denmark tracker
Sponsor
University of Aarhus
Phase
Observational
Started
2016-09
Last updated
2022-08-12

Condition(s) studied

Primary Biliary CirrhosisLiver Inflammation

Investigational drug(s) / intervention(s)

Blood samples, fibroscan and questionaires

Study summary

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR correlate with disease severity in patients with PBC, and whether sCD163 and sMR can predict short term disease progression, changes in quality of life and death in these patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosed with primary biliary cholangitis Exclusion Criteria: * Patient under 18 years * Expected lifetime below 6 months * Planned liver transplantation within 6 months * Cirrhosis from other causes (except autoimmune hepatitis) * Liver cancer

Primary outcome measure(s)

  • Disease progression (Blood samples) — 3 years
  • All-cause mortality (Information from medical journal) — 3 years
  • Liver stiffness (fibroscan) — 3 years

Trial sites (1)

FacilityCityRegionStatus
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark Aarhus C Central Jutland

More University of Aarhus trials in Denmark

Probiotic Treatment of Orthodontic Patients Recruiting
BPA vs. PEA in CTEPH Recruiting
Precision Treatment of Lumbar Spine Surgery Through Advanced Nerve Root Blockade Recruiting
IMPROVE: Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer Active, not recruiting
Danish Access to Support and Help (DASH): Increasing Access to an Evidence-based Intervention for Children With ADHD and Their Parents Enrolling by invitation

Other trials for the same condition

sCD163 in PBC Patients - Assessment of Treatment Response Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02924701 on ClinicalTrials.gov ↗ ← All trials in Denmark